Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Allorion Therapeutics
Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
Allorion Rides Unconventional Discovery Platforms To Major Funding
Allorion's key innovative attractions include discovery platforms for allosteric inhibitor screening and the discovery of synthetic lethality targets/molecules, along with a small but growing pipeline of novel assets. Founded in 2020, the China- and US-based biotech has now raised more than $100m in three financing deals, including a $50m series B.
Finance Watch: Dementia Discovery Fund’s Behr Sees Early Investments Reviving Neuroscience Interest
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.
Abogen and Neurophth Lead China mRNA, Gene And Cell Therapy Funding Rush
Total of $571m raised in China from 10 venture capital and private equity funding deals betting heavily on mRNA and targeted oncology, as well as gene and cell therapies.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.